Background Immune-mediated therapies have transformed the treatment of metastatic
melanoma and renal, bladder, and both small and non-small cell lung carcinomas …

For medulloblastoma patients, the current therapeutic paradigm of surgery followed by
radiation and chemotherapy can lead to long-term remission. However, the sequelae of …

Simple Summary Medulloblastoma (MB) is a primary brain tumor and is one of the most
prevalent neoplasms in the pediatric age group, with a median age of diagnosis of six years …

Medulloblastoma (MB) is the most common malignant brain tumor in children, making up~
20% of all primary pediatric brain tumors. Current therapies consist of maximal surgical …

Opinion statement Medulloblastoma (MB) is the most common pediatric brain malignancy,
with a 5-year overall survival (OS) rate of around 65%. The conventional MB treatment …

Medulloblastoma is the most common primary pediatric malignancy of the central nervous
system. Recurrent and refractory patients account for approximately 30% of them. Immune …

Medulloblastoma is an aggressive brain tumor that occurs predominantly in children.
Despite intensive therapy, many patients die of the disease, and novel therapies are …

Pediatric central nervous system tumors are the most common solid malignancies in
childhood, and aggressive therapy often leads to long-term sequelae in survivors, making …

Medulloblastoma (MB) is the most common cerebellar neoplasm in the pediatric population.
Treatment is based on multidisciplinary therapy with maximal safe resection surgery …

Pediatric medulloblastomas are the most frequently diagnosed embryonal tumors of the
central nervous system. Current therapies cause severe neurological and cognitive side …